4.26

2.40% 0.10

4 D Molecular Therapeutics Inc (FDMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.16

Offen:

$4.2

24-Stunden-Volumen:

319.65K

Relative Volume:

0.70

Marktkapitalisierung:

$197.34M

Einnahmen:

$20.72M

Nettoeinkommen (Verlust:

$-100.84M

KGV:

-1.6015

EPS:

-2.66

Netto-Cashflow:

$-78.56M

1W Leistung:

-3.62%

1M Leistung:

-2.52%

6M Leistung:

-8.97%

1J Leistung:

-84.07%

1-Tages-Spanne:

$4.20

$4.3385

1-Wochen-Bereich:

$4.11

$4.50

52-Wochen-Spanne:

$2.235

$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Firmenname

4 D Molecular Therapeutics Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (659)

Telefon

(510) 505-2680

Adresse

5858 HORTON STREET #455, EMERYVILLE

Mitarbeiter

227

Twitter

Nächster Verdiensttermin

2024-12-13

Neueste SEC-Einreichungen

FDMT's Discussions on Twitter

Vergleichen Sie FDMT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FDMT 4 D Molecular Therapeutics Inc	4.26	204.75M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	469.55	123.00B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.93	59.66B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.81	41.84B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	577.92	33.98B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	279.16	27.67B	3.81B	-644.79M	-669.77M	-6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-13	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Eingeleitet	Morgan Stanley	Underweight
2024-09-23	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Eingeleitet	Barclays	Overweight
2024-02-07	Fortgesetzt	Goldman	Buy
2023-10-26	Eingeleitet	RBC Capital Mkts	Outperform
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-18	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-07-05	Eingeleitet	Chardan Capital Markets	Buy
2023-01-30	Eingeleitet	BMO Capital Markets	Outperform
2022-11-18	Eingeleitet	H.C. Wainwright	Buy
2022-11-15	Hochstufung	Goldman	Neutral → Buy
2022-08-12	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Eingeleitet	Jefferies	Buy
2022-01-04	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	BofA Securities	Buy
2021-01-05	Eingeleitet	Evercore ISI	Outperform
2021-01-05	Eingeleitet	Goldman	Neutral

Alle ansehen

4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten

Jul 15, 2025

What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser

Jul 15, 2025

Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Signals Group - Newser

Jul 15, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser

Jul 15, 2025

Jul 14, 2025

Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 14, 2025

Jul 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Jul 11, 2025

Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan

Jul 11, 2025

Jul 10, 2025

4D Molecular to layoff about 25% of workforce - MSN

Jul 10, 2025

Jul 07, 2025

Promising Penny Stocks To Consider In July 2025 - simplywall.st

Jul 07, 2025

Jul 05, 2025

Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 05, 2025

Jul 03, 2025

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Nasdaq

Jul 03, 2025

Jul 02, 2025

East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals

Jul 02, 2025

4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener

Jul 02, 2025

4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire

Jul 02, 2025

Jun 30, 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025

Jun 28, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jun 28, 2025

Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025

Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025

Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025

Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025

Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jun 10, 2025

Jun 05, 2025

4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Jun 05, 2025

Jun 04, 2025